No description available.

Carbapenem-resistant Acinetobacter baumannii is the top-ranked pathogen in the World Health Organization priority list of antibiotic-resistant bacteria. It emerged as a global pathogen due to the successful expansion of a few epidemic lineages, or international clones (ICs), producing acquired class D carbapenemases (OXA-type). During the past decade, however, reports regarding IC-I isolates in Latin America are scarce and are non-existent for IC-II and IC-III isolates. This study evaluates the molecular mechanisms of carbapenem resistance and the epidemiology of 80 non-duplicate clinical samples of A. baumannii collected from February 2014 through April 2016 at two tertiary care hospitals in Lima. Almost all isolates were carbapenem-resistant (97.5%), and susceptibility only remained high for colistin (95%). Pulsed-field gel electrophoresis showed two main clusters spread between both hospitals: cluster D containing 51 isolates (63.8%) associated with sequence type 2 (ST2) and carrying OXA-72, and cluster F containing 13 isolates (16.3%) associated with ST79 and also carrying OXA-72. ST2 and ST79 were endemic in at least one of the hospitals. ST1 and ST3 OXA-23-producing isolates were also identified. They accounted for sporadic hospital isolates. Interestingly, two isolates carried the novel OXA-253 variant of OXA-143 together with an upstream novel insertion sequence (ISAba47). While the predominant A. baumannii lineages in Latin America are linked to ST79, ST25, ST15, and ST1 producing OXA-23 enzymes, we report the emergence of highly resistant ST2 (IC-II) isolates in Peru producing OXA-72 and the first identification of ST3 isolates (IC-III) in Latin America, both considered a serious threat to public health worldwide. / This study was supported by Cienciactiva of CONCYTEC, contract no. 164-2016-FONDECYT; Planes Nacionales de I+D+i 2008-2011/2013-2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0013 and REIPI RD16/0016/ 0010); the 2017 call for Strategic Action on Health (PI17/01932), co-financed by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014-2020; and grant 2014 SGR 0653 from the Departament d’Universitats, Recerca i Societat de la Informació, of the Generalitat de Catalunya. I.R. was supported by the Department of Health, Generalitat de Catalunya, grant SLT002/16/00349. Part of these data have been presented as a poster communication at the 18th International Congress on Infectious Diseases, 3–4 March, 2018, Buenos Aires, Argentina, and at the XXVIII-European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid (Spain), 21–24 April, 2018 / Revisión por pares

Escherichia coli and Klebsiella pneumoniae isolates were obtained from the Canadian Ward Surveillance Study (CANWARD) and underwent in vitro susceptibility testing to determine prevalence and antimicrobial resistance patterns. The prevalence was found to be relatively stable over the years although there was an increase in prevalence among the K. pneumoniae isolates; 1.1% to 1.3% to 2.5% to 2.6% in 2007, 2008, 2009, and 2010, respectively. Genotypic characterization was conducted on ESBL, AmpC, carbapenemase genes, and outer membrane porins. The highest proportion of isolates were found to produce CTX-M-15 β-lactamase. Only 1 of each KPC-producing E. coli and K. pneumoniae was found. Porin alteration was found to be a factor leading to carbapenem reduced susceptibility among isolates. Genetic relatedness of CRS/CIR E. coli and K. pneumoniae was determined using pulsed-field gel electrophoresis. The spread of these organisms was mainly due to polyclonal spread rather than one specific clone.

Escherichia coli and Klebsiella pneumoniae isolates were obtained from the Canadian Ward Surveillance Study (CANWARD) and underwent in vitro susceptibility testing to determine prevalence and antimicrobial resistance patterns. The prevalence was found to be relatively stable over the years although there was an increase in prevalence among the K. pneumoniae isolates; 1.1% to 1.3% to 2.5% to 2.6% in 2007, 2008, 2009, and 2010, respectively. Genotypic characterization was conducted on ESBL, AmpC, carbapenemase genes, and outer membrane porins. The highest proportion of isolates were found to produce CTX-M-15 β-lactamase. Only 1 of each KPC-producing E. coli and K. pneumoniae was found. Porin alteration was found to be a factor leading to carbapenem reduced susceptibility among isolates. Genetic relatedness of CRS/CIR E. coli and K. pneumoniae was determined using pulsed-field gel electrophoresis. The spread of these organisms was mainly due to polyclonal spread rather than one specific clone.

Magister Pharmaceuticae - MPharm / Antimicrobial resistance is a global concern associated with increased morbidity and mortality. It has been estimated that, by 2050, the continuous escalation of antimicrobial resistance, globally, will result in more deaths per year, compared to cancer and diabetes. The direct and indirect impact of ineffective antibiotics, and therefore, antimicrobial resistance, will be hardest felt by low and middle-income countries, as the financial burden will be too great to manage. Carbapenems are considered the last line of antimicrobials to treat multidrug-resistant bacterial infections. They are the preferred choice to treat infections, presenting with extended-spectrum beta-lactamases (ESBL) producing Enterobacteriacea. Various strains of bacteria that have become resistant, due to the selective pressure, as a result of carbapenem over use, are referred to as Carbapenem-resistant Enterobacteriaceae (CRE). / 2022

No description available.

No description available.

As antibiotic resistant bacterial strains are becoming more prevalent in healthcare settings, it is necessary to find alternative methods of detecting and treating these infections. One of the antibiotic resistant strains of interest is the carbapenem-resistant Enterobacteriaceae (CRE). CREs have the ability to evade some of the most potent antibiotics currently in use and employ carbapenemases to negate the effect of antibiotics. The three most common carbapenemase genes, found in carbapenem-resistant Enterobacteriaceae along with a gene found only in Escherichia coli were chosen to create a qPCR assay for rapid detection of resistant infections. The carbapenemase genes are KPC, VIM and NDM and the E. coli gene is uidA, a β-glucuronidase gene. Consensus sequences were obtained from each of the genes to account for the many variants of each gene. We were able to triplex the assay and test it against a library for twenty isolates varying by which gene they contain. Additional research has been conducted on the library of carbapenem-resistant Enterobacteriaceae using bacteriophages or phage. The Phage Hunters class isolated and identified twenty phage that infect K. pneumoniae. Out of the twenty phage, seven phage were able to effectively infect carbapenem-resistant K. pneumoniae.

Acinetobacter baumannii, microorganisme responsable d’infections nosocomiales survenant le plus souvent par épidémies, pose un problème émergent de multi-résistance aux antibiotiques, notamment aux carbapénèmes. Cette résistance aux carbapénèmes est le plus souvent liée à l’acquisition et à l’expression de gènes codant pour des b-lactamases de classe D à activité de carbapénèmase (CHDLs). Le réservoir de ces gènes de résistance est inconnu.Nous avons montré que l’espèce bactérienne Acinetobacter radioresistens, espèce proche de A. baumannii, est le progéniteur du déterminant de résistance aux carbapénèmes le plus prévalent dans le monde chez A. baumannii : le gène blaOXA-23. Nous avons identifié l’espèce Acinetobacter lwoffii comme progéniteur d’un gène codant pour une nouvelle CHDL : OXA-134. Nous avons identifié les CHDLs naturelles des espèces Acinetobacter johnsonii, Acinetobacter calcoaceticus et Acinetobacter haemolyticus, dénommées respectivement OXA-211, OXA-213 et OXA-214. Nous avons ensuite étudié l’expression des gènes codant pour ces CHDLs naturelles en prenant l’exemple du gène naturel blaOXA-51/-66 de A. baumannii et nous avons démontré que ce gène était impliqué dans la réduction de sensibilité aux carbapénèmes chez A. baumannii, notamment lorsque la séquence d’insertion (IS) ISAba1 était présente en amont de ce gène. Nous avons ensuite identifié une nouvelle IS, ISAba9, à l’origine de la surexpression du gène blaOXA-51 naturel de A. baumannii. Enfin, nous avons identifié VIM-4, b-lactamase de classe B capable d’hydrolyser les carbapénèmes, dans une souche de Acinetobacter non-baumannii, Acinetobacter genomic species 16. / Carbapenem resistance in Acinetobacter baumannii is increasingly reported and leads to difficult-to-treat nosocomial infections. Carbapenem-hydrolyzing class D b-lactamases (CHDLs) represent the main mechanism of resistance to carbapenems in Acinetobacter spp. The origin (reservoir) of those CHDL genes remains unknown. We identified Acinetobacter radioresistens as the reservoir of the blaOXA-23-like genes currently emerging as the sources of carbapenem resistance in A. baumannii worldwide. Acinetobacter lwoffii was found to be a reservoir of a novel type of CHDL-encoding gene: blaOXA-134. We described the naturally-occurring CHDLs from Acinetobacter johnsonii, Acinetobacter calcoaceticus and Acinetobacter haemolyticus, respectively named OXA-211, OXA-213 et OXA-214. We reported an in vivo selection of reduced susceptibility to carbapenems in A. baumannii. This reduced susceptibility to carbapenems was related to selection of the ISAba1-related overexpression of the naturrally-occurring blaOXA-51/-69 gene from A. baumannii. We identified the novel insertion sequence ISAba9 as being involved in blaOXA-51/-69 gene overexpression, thus contributing to carbapenem resistance in A. baumannii.We reported the first identification of the metallo-b-lactamase VIM-4 determinant in Acinetobacter spp.

No description available.